

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 February 2022 (10.02.2022)



(10) International Publication Number
WO 2022/031666 A1

(51) International Patent Classification:

A61K 9/20 (2006.01) *A61P 3/14* (2006.01)
A61K 31/195 (2006.01) *A61P 19/10* (2006.01)
A61K 47/26 (2006.01) *A61P 29/00* (2006.01)
A61K 47/38 (2006.01)

(21) International Application Number:

PCT/US2021/044295

(22) International Filing Date:

03 August 2021 (03.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/061,050 04 August 2020 (04.08.2020) US

(71) Applicant: **CALCILYTIX THERAPEUTICS, INC.**
[US/US]; 1800 Owens St., Ste. C-1200, San Francisco, California 94158 (US).

(72) Inventors: **SINHA, Uma**; c/o Calcilytix Therapeutics, Inc., 1800 Owens St., Ste. C-1200, San Francisco, California 94158 (US). **SRIDHAR, Ananth**; c/o Calcilytix Therapeutics, Inc., 1800 Owens St., Ste. C-1200, San Francisco, California 94158 (US). **PRASAD, Leena**; 1800 Owens St., Ste. C-1200, San Francisco, California 94158 (US).

KOMEYLI, Ali; c/o Calcilytix Therapeutics, Inc., 1800 Owens St., Ste. C-1200, San Francisco, California 94158 (US).


(74) Agent: **DONG, Yaohua** et al.; Mintz Levin Cohn Ferris Glovsky & Popeo, P.C., One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: FORMULATIONS OF TRIPHENYL CALCILYTIC COMPOUNDS

FIG. 1



(57) Abstract: The present disclosure provides tablet formulations including a triphenyl calcilytic compound for the treatment of autosomal dominant hypocalcemia (ADH), where the compound is represented by formula (I): a solvate, a hydrate, a pharmaceutically acceptable salt, or a combination thereof.



[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*